ABBOTT LABORATORIES — Director's Dealing 2019

Apr 4, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-04-01

Reporting Person: Scoggins Christopher J (Senior Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	25300	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$48.04	2025-06-14	Common shares (47226)		Direct
Option (right to buy)	$38.40	2026-02-18	Common shares (15000)		Direct
Option (right to buy)	$44.40	2027-02-16	Common shares (22196)		Direct
Option (right to buy)	$59.94	2028-02-15	Common shares (64449)		Direct
Option (right to buy)	$75.90	2029-02-21	Common shares (51557)		Direct

Footnotes

F1: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on June 15, 2016, 15,742 on June 15, 2017, and 15,742 on June 15, 2018.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments and became fully exercisable on February 19, 2019.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 7,399 and 7,398 became exercisable on February 17, 2018 and February 17, 2019, respectively, and 7,399 becomes exercisable on February 17, 2020.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 21,483 became exercisable on February 16, 2019 and 21,483 and 21,483 becomes exercisable on February 16, 2020 and February 16, 2021, respectively.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,185 on February 22, 2020, 17,186 on February 22, 2021, and 17,186 on February 22, 2022.